Sailing Near the Wind: Why "Export-Only" and "House Mark" Defenses Fail in Pharmaceutical Trademark Infringement—A Deep Dive into Sun Pharma v. Absun Pharma.
In the high-stakes world of pharmaceutical branding, companies often believe that subtle modifications or niche business models—such as "export-only" operations—provide a safe harbor against trademark infringement claims. However, a recent landmark judgment by the Bombay High Court in Sun Pharmaceutical Industries Ltd. v. Satej M. Katekar serves as a masterclass in the rigors of Indian Intellectual Property law. The ruling dismantles several common defenses used by smaller players when pitted against established giants, reinforcing that in the eyes of the law, "sailing near the wind" is a perilous strategy.
The "House Mark" is Not a ShieldOne of the most intriguing aspects of this case was the defendant's attempt to distinguish between a "product mark" and a "house mark". The defendant argued that 'ABSUN' was merely a house mark (a corporate identity) and not a specific brand name for a medicine, suggesting that consumers primarily look at product names. The Court was unimpressed. It clarified that the Trade Marks Act, 1999, does not recognize a legal distinction between the two. If a mark is capable of distinguishing the goods of one person from another, it is a trade mark, regardless of whether you call it a house mark or a brand.
This is a vital reminder for businesses: you cannot bypass infringement by claiming your infringing mark is "just the company name" appearing on the back of the packaging. If it identifies the source, it falls under the scanner of Section 29 of the Act.
The "Export-Only" FallacyPerhaps the most impactful takeaway for global traders is the Court's interpretation of Section 56 of the Trade Marks Act. The defendant argued that since 100% of their products were exported to African countries and never sold in India, there was no "use" of the mark in India, and thus no passing off or infringement. The Court categorically rejected this, noting that the act of applying a mark to goods in India, even if those goods are destined for foreign shores, constitutes "use" within the country.
"The plain language of section 56, therefore, constitutes the application in India of trade marks even to goods to be exported from India as use of the trade mark in relation to those goods for any purpose for which such use is material under the Act or any other law."
This ensures that India cannot be used as a manufacturing hub for counterfeit or infringing goods intended for international markets, upholding the integrity of the global supply chain.
The Danger of "Sailing Near the Wind"The defendant claimed "honest adoption", stating 'ABSUN' was coined from his son’s name (Abheejit) and his wife’s name (Sunita). While this sounds like a relatable origin story, the Court found it legally irrelevant once deceptive similarity was established. The Court observed that the defendant was aware of Sun Pharma’s existence since 1995. By prefixing 'AB' to the registered mark 'SUN', the defendant was attempting to trade on the plaintiff's hard-earned goodwill.
The judgment invokes a powerful maritime metaphor: "honest men do not attempt to sail near the wind." In trademark law, if you choose a name that is "close enough" to a famous brand to cause confusion, your intentions—no matter how sentimental—will not save you from an injunction.
The Procedural Trap: Commercial Suits are DifferentFor legal practitioners, the case highlights the "procedural teeth" of the Commercial Courts Act. The defendant tried to challenge the validity of the plaintiff’s sales certificates because the Chartered Accountants who issued them weren't called as witnesses. Usually, this might be a strong evidentiary objection. However, because this was a Commercial Suit, the rules of "Admission and Denial" under the CPC were strictly applied. Since the defendant failed to specifically deny the documents during the early stages of the trial, the documents were deemed "admitted".
This underscores a critical lesson: in commercial litigation, procedural lapses regarding the admission of documents can be fatal. You cannot wait until the final hearing to challenge the "correctness" of a document you failed to deny at the outset.
Conclusion: A Stricter Standard for PharmaUltimately, the Court reiterated that when it comes to medicinal preparations, the "stricter test" applies. Confusion in branding isn't just a commercial loss; it is a public health risk. By awarding Rs. 10 lakhs in costs against the defendant, the Court sent a clear message: the cost of infringement is high, and the protection of registered marks is absolute, regardless of where the goods are eventually consumed.
Case: SUN PHARMACEUTICAL INDUSTRIES LTD v. SATEJ M KATEKAR PROP OF ABSUN PHARMA
Law: Trade Marks Act, Commercial Courts Act, Code of Civil Procedure.
Citation: 2026:BHC-OS:10273
Decision Date: 22-04-2026